更新于：2024-04-01

CD40

肿瘤坏死因子受体超家族成员5

更新于：2024-04-01

基本信息

别名

CD40抗原、B-cell surface antigen CD40、Bp50

+ [9]

简介

Receptor for TNFSF5/CD40LG (PubMed:31331973). Transduces TRAF6- and MAP3K8-mediated signals that activate ERK in macrophages and B cells, leading to induction of immunoglobulin secretion (By similarity).

关联

项与 CD40 相关的药物

Anti-CD40 ChiLob7/4(BioNTech SE)

靶点

CD40

作用机制

CD40激动剂

在研机构

BioNTech SE

原研机构

BioNTech SE

在研适应症

头颈部肿瘤 [+1]

非在研适应症-

最高研发阶段临床2期

首次获批国家/地区-

首次获批日期1800-01-20

Iscalimab

靶点

CD40

作用机制

CD40抑制剂

在研机构

Novartis Pharmaceuticals Corp. [+3]

原研机构

Novartis Pharma AG

在研适应症

肝移植排斥反应 [+3]

非在研适应症

肾移植排斥反应

最高研发阶段临床2期

首次获批国家/地区-

首次获批日期1800-01-20

CD40L-GVAX

靶点

CD40 x CSF-2R

作用机制

CD40激动剂 [+1]

在研机构

University of South Florida [+1]

原研机构

University of South Florida

在研适应症

肺癌 [+1]

非在研适应症

肺腺癌 [+1]

最高研发阶段临床2期

首次获批国家/地区-

首次获批日期1800-01-20

183

项与 CD40 相关的临床试验

NCT06159621 / Not yet recruiting临床1期IIT

Neoadjuvant/Phase 1 Study of CD40 Agonist (LVGN7409) and PD-1 Inhibitor (LVGN3616) in Patients With Resectable HPV-negative Head/Neck Squamous Cell Carcinoma (HNSCC)

Prospective, open-label, phase 1 study of CD40 agonist (LVGN7409) and PD-1 inhibition (LVGN3616) in patients with resectable Human Papillomavirus (HPV)-negative mucosal head/neck squamous cell carcinoma (HNSCC). This protocol proposes to study the safety and immunological effects of LVGN7409, a CD40 agonistic antibody, when administered in combination with PD-1 inhibition prior to surgical resection.

开始日期2024-05-01

申办/合作机构

University of Pennsylvania

NCT05849480 / Not yet recruiting临床1/2期IIT

A Phase I/II Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)

Background:
Biliary tract carcinoma (BTC) is cancer of the slender tubes that carry fluids in the liver. People with advanced BTC have few treatment options, and their survival rates are very low.
Objective:
To test a study drug (CDX-1140) combined 3 other drugs (capecitabine, oxaliplatin, Keytruda) in people with BTC.
Eligibility:
Adults aged 18 years or older with BTC that progressed after treatment and is not eligible for surgery or liver transplant.
Design:
Participants will be screened. They will have a physical exam. They will have blood tests and tests of their heart function. They will have imaging scans. They may need to have a biopsy: A small sample of tissue will be taken from their tumor using a small needle.
Three of the drugs are given through a tube attached to a needle inserted into a vein in the arm (intravenous). The fourth drug is a pill taken by mouth with water.
Participants will be treated in 21-day cycles. They will receive intravenous treatments on day 1 and day 8 of the first 6 cycles. After that, they will receive intravenous treatments only on day 1 of each cycle.
Participants will take the pill twice a day only for the first 2 weeks of each cycle. They will stop taking this drug after 6 cycles.
Imaging scans will be repeated every 9 weeks.
Participants may continue receiving the study treatment for up to 2 years. Follow-up visits, including imaging scans, will continue for 3 more years. These images may be taken at other locations and sent to the researchers.

开始日期2024-04-03

申办/合作机构

National Cancer Institute

CTR20234253 / Recruiting临床1期

评价LNF1901治疗晚期恶性肿瘤患者的安全性、耐受性、药代动力学特征及初步有效性的I期临床研究

评价LNF1901治疗晚期恶性肿瘤患者的安全性、耐受性、药代动力学特征及初步有效性

开始日期2024-03-01

申办/合作机构

山东新时代药业有限公司

100 项与 CD40 相关的临床结果

登录后查看更多信息

100 项与 CD40 相关的转化医学

登录后查看更多信息

0 项与 CD40 相关的专利（医药）

登录后查看更多信息

11,642

项与 CD40 相关的文献（医药）

2024-12-01·Bioengineered

Genetically engineered IgG1 and nanobody oligomers acquire strong intrinsic CD40 agonism.

Article

作者: Nienke Hesen ; Mohamed Anany ; Andre Freidel ; Mediya Baker ; Daniela Siegmund ; Olena Zaitseva ; Harald Wajant ; Isabell Lang

Most anti-CD40 antibodies show robust agonism only upon binding to FcγR⁺ cells, such as B cells, macrophages, or DCs, but a few anti-CD40 antibodies display also strong intrinsic agonism dependent on the recognized epitope and/or isotype. It is worth mentioning, however, that also the anti-CD40 antibodies with intrinsic agonism can show a further increase in agonistic activity when bound by FcγR-expressing cells. Thus, conventional antibodies appear not to be sufficient to trigger the maximum possible CD40 activation independent from FcγR-binding. We proved here the hypothesis that oligomeric and oligovalent anti-CD40 antibody variants generated by genetic engineering display high intrinsic, thus FcγR-independent, agonistic activity. We generated tetra-, hexa- and dodecavalent variants of six anti-CD40 antibodies and a CD40-specific nanobody. All these oligovalent variants, even when derived of bivalent antagonistic anti-CD40 antibodies, showed strongly enhanced CD40 agonism compared to their conventional counterparts. In most cases, the CD40 agonism reached the maximum response induced by FcγR-bound anti-CD40 antibodies or membrane CD40L, the natural engager of CD40. In sum, our data show that increasing the valency of anti-CD40 antibody constructs by genetic engineering regularly results in molecules with high intrinsic agonism and level out the specific limitations of the parental antibodies.

2024-05-01·Carbohydrate polymers

An arabinose-rich heteropolysaccharide isolated from Belamcanda chinensis (L.) DC treats liver cancer by targeting FAK and activating CD40

Article

作者: Zhao, Yinan ; Hou, Jiantong ; Liu, Yuhui ; Xu, Jing ; Guo, Yuanqiang

An undisclosed polysaccharide, BCP80-2, was isolated from Belamcanda chinensis (L.) DC. Structural investigation revealed that BCP80-2 consists of ten monosaccharide residues including t-α-Araf-(1→, →3,5)-α-Araf-(1→, →5)-α-Araf-(1→, →4)-β-Xylp-(1→, →3)-α-Rhap-(1→, →4)-β-Manp-(1→, t-β-Glcp-(1→, →6)-α-Glcp-(1→, t-β-Galp-(1→, and→3)-α-Galp-(1→. In vivo activity assays showed that BCP80-2 significantly suppressed neoplasmic growth, metastasis, and angiogenesis in zebrafish. Mechanistic studies have shown that BCP80-2 inhibited cell migration of HepG2 cells by suppressing the FAK signaling pathway. Moreover, BCP80-2 also activated immunomodulation and upregulated the secretion of co-stimulatory molecules CD40, CD86, CD80, and MHC-II. In conclusion, BCP80-2 inhibited tumor progression by targeting the FAK signaling pathway and activating CD40-induced adaptive immunity.

2024-03-01·The World Allergy Organization journal

Assessment of serum soluble CD40 ligand levels in patients with chronic rhinosinusitis.

Article

作者: Zhichen Liu ; Yuhui Fan ; Aina Zhou ; Jisheng Liu ; Qingqing Jiao

Chronic rhinosinusitis (CRS) is a disease highly associated with abnormal regulation of T and B cells. The underlying pathophysiology of inflammatory pathways has critical implications for the diagnosis and management of CRS. Soluble CD40-ligand (sCD40L) is a cleaved form of CD40L present in plasma which functions the same way as CD40L, which has been observed as an inflammatory biomarker in many diseases. CD40L-positive cells control B-cell maturation, proliferation, apoptosis, and antibody production by binding to its receptor CD40 on B-cells. And our results show for the first time that patients with CRS have lower serum sCD40L levels compared to healthy subjects and that decreased sCD40L levels in patients correlate with increased CD40L-positive cell counts in the sinonasal mucosa. In addition, eosinophilic chronic rhinosinusitis (eCRS) patients tend to exhibit more CD40L-positive cells in the sinonasal mucosa compared to non-eCRS patients. This supports the notion that local blockade of CD40/CD40L may suppress pathogenic T/B cell responses and reduce tissue inflammation. Significantly, sCD40L and CD40L may be involved in the development and progression of CRS by impairing peripheral blood B-cell function and enhancing the local inflammatory response in the sinonasal mucosa.

1,322

项与 CD40 相关的新闻（医药）

2024-03-29

·医药笔记

绿叶制药：重组带疱疫苗启动一期临床

▎Armstrong2024年3月28日，绿叶制药子公司派诺生物在Clinicaltrials.gov网站上注册了重组带疱疫苗LYB004的澳洲一期临床试验。该一期临床计划入组48例50-70岁的健康志愿者，预计2025年2月完成。该一期临床探索25ug、50ug两个剂量组，同时以葛兰素史克的Shingrix为对照组。根据派诺生物专利信息，LYB004为一款纳米颗粒疫苗。纳米颗粒疫苗的技术路线如下，纳米颗粒蛋白选自NPM、AP205或Ferritin。抗原蛋白与纳米颗粒蛋白制成均一大小的纳米颗粒。相比于Shingrix，gE-NPM等纳米颗粒疫苗表现出更好的免疫原性，包括体液免疫和细胞免疫。总结国内带状疱疹疫苗市场处于爆发阶段，葛兰素史克/智飞Shingrix快速增长，百克生物减毒活疫苗2023年销售额8.8亿元。绿竹生物、怡道生物处于三期临床阶段，迈科康处于二期临床阶段，华诺泰、瑞科生物处于一期临床，吉诺卫、智飞生物、远大赛微信、中慧元通等陆续申报IND，嘉晨西海、深信生物开发了带疱mRNA疫苗。Armstrong技术全梳理系列GPRC5D靶点全梳理；CD40靶点全梳理；CD47靶点全梳理；补体靶向药物技术全梳理；补体药物：眼科治疗的重要方向；Claudin 6靶点全梳理；Claudin 18.2靶点全梳理；靶点冷暖，行业自知；中国大分子新药研发格局；被炮轰的“me too”；佐剂百年史；胰岛素百年传奇；CUSBEA：风雨四十载；中国新药研发的焦虑；中国生物医药企业的研发竞争；中国双抗竞争格局；中国ADC竞争格局；中国双抗技术全梳理；中国ADC技术全梳理；Ambrx技术全梳理；Vir Biotech技术全梳理；Immune-Onc技术全梳理；亘喜生物技术全梳理；康哲药业技术全梳理；科济药业技术全梳理；恺佧生物技术全梳理；同宜医药技术全梳理；百奥赛图技术全梳理；腾盛博药技术全梳理；创胜集团技术全梳理；永泰生物技术全梳理；中国抗体技术全梳理；德琪医药技术全梳理；德琪医药技术全梳理2.0；和铂医药技术全梳理；荣昌生物技术全梳理；再鼎医药技术全梳理；药明生物技术全梳理；恒瑞医药技术全梳理；豪森药业技术全梳理；正大天晴技术全梳理；吉凯基因技术全梳理；基石药业技术全梳理；百济神州技术全梳理；百济神州技术全梳理第2版；信达生物技术全梳理；信达生物技术全梳理第2版；中山康方技术全梳理；复宏汉霖技术全梳理；先声药业技术全梳理；君实生物技术全梳理；嘉和生物技术全梳理；志道生物技术全梳理；道尔生物技术全梳理；尚健生物技术全梳理；康宁杰瑞技术全梳理；科望医药技术全梳理；科望医药技术全梳理2.0；岸迈生物技术全梳理；礼进生物技术全梳理；康桥资本技术全梳理；余国良的抗体药布局；荃信生物技术全梳理；安源医药技术全梳理；三生国健技术全梳理；仁会生物技术全梳理；乐普生物技术全梳理；同润生物技术全梳理；宜明昂科技术全梳理；派格生物技术全梳理；迈威生物技术全梳理；Momenta技术全梳理；NGM技术全梳理；普米斯生物技术全梳理；普米斯生物技术全梳理2.0；三叶草生物技术全梳理；贝达药业抗体药全梳理；泽璟制药抗体药全梳理；恒瑞医药抗体药全梳理；齐鲁制药抗体药全梳理；石药集团抗体药全梳理；豪森药业抗体药全梳理；华海药业抗体药全梳理；科伦药业抗体药全梳理；百奥泰技术全梳理；凡恩世技术全梳理。

临床2期疫苗临床1期信使RNA抗体药物偶联物

2024-03-29

·医药笔记

和铂医药：2023年首次实现盈利1.6亿元

▎Armstrong2024年3月28日，和铂医药发布2023年财报，公司收入连续三年实现指数级增长，2023年收入6.4亿元，同时首次实现全年盈利1.6亿元。良好的业绩表现同时得益于开源和节流，高效成本管理使得运营成本大幅下降，从2022年到2023年，研发成本从11.5亿元下降到4.7亿元，行政开支从1.9亿元下降到1.4亿元，现金储备从12.2亿元增加到13.6亿元。高效成本管理的前提仍然是坚持创新布局，技术平台和产品屡获MNC等认可，从2020年到2023年，公司连续完成高额License-out交易，同时也成为开源增收的主要来源。更重要的是，建立在技术平台基础上的创新，可以源源不断输出创新产品，保证这种增长模式的持续性，同时合作伙伴的临床进展将进一步带来潜在的里程碑收入和销售分成收入，助推公司业绩节节攀升。值得注意的是，和铂医药的完整创新体系撑起了多元化商业拓展的格局，合作领域覆盖细胞治疗、抗体、AI制药、mRNA疗法、ADC等多种药物形式。凭借扎实的创新布局，和铂医药已经搭建起丰富、具特色的研发管线梯队，内部管线临床进展不断，对外合作项目不断增加的同时其临床开发也在稳步推进，临床前不断输出更多创新产品。例如，2023年8月，合作伙伴阿斯利康启动Claudin18.2/CD3双抗的全球1/2期临床，计划入组200例晚期实体瘤患者。内部核心管线方面，巴托利单抗在gMG三期临床获得成功，成为中国第一款FcRn靶向的皮下注射产品，相比静脉注射产品使用便利性更好。和铂医药CTLA-4抗体与PD-1抗体联合治疗在多种肿瘤中表现出良好的疗效。总结和铂医药走出了一条独特的发展路径，创新技术平台和产品互相反哺，低成本运营的同时能保证创新平台高效输出新的产品，商业模式上自主开发和授权出海并重，实现全球商业价值。授权产品的预付款、里程碑收入、销售分成等形成稳定增长的收入来源，助推公司业绩节节攀升。Armstrong技术全梳理系列GPRC5D靶点全梳理；CD40靶点全梳理；CD47靶点全梳理；补体靶向药物技术全梳理；补体药物：眼科治疗的重要方向；Claudin 6靶点全梳理；Claudin 18.2靶点全梳理；靶点冷暖，行业自知；中国大分子新药研发格局；被炮轰的“me too”；佐剂百年史；胰岛素百年传奇；CUSBEA：风雨四十载；中国新药研发的焦虑；中国生物医药企业的研发竞争；中国双抗竞争格局；中国ADC竞争格局；中国双抗技术全梳理；中国ADC技术全梳理；Ambrx技术全梳理；Vir Biotech技术全梳理；Immune-Onc技术全梳理；亘喜生物技术全梳理；康哲药业技术全梳理；科济药业技术全梳理；恺佧生物技术全梳理；同宜医药技术全梳理；百奥赛图技术全梳理；腾盛博药技术全梳理；创胜集团技术全梳理；永泰生物技术全梳理；中国抗体技术全梳理；德琪医药技术全梳理；德琪医药技术全梳理2.0；和铂医药技术全梳理；荣昌生物技术全梳理；再鼎医药技术全梳理；药明生物技术全梳理；恒瑞医药技术全梳理；豪森药业技术全梳理；正大天晴技术全梳理；吉凯基因技术全梳理；基石药业技术全梳理；百济神州技术全梳理；百济神州技术全梳理第2版；信达生物技术全梳理；信达生物技术全梳理第2版；中山康方技术全梳理；复宏汉霖技术全梳理；先声药业技术全梳理；君实生物技术全梳理；嘉和生物技术全梳理；志道生物技术全梳理；道尔生物技术全梳理；尚健生物技术全梳理；康宁杰瑞技术全梳理；科望医药技术全梳理；科望医药技术全梳理2.0；岸迈生物技术全梳理；礼进生物技术全梳理；康桥资本技术全梳理；余国良的抗体药布局；荃信生物技术全梳理；安源医药技术全梳理；三生国健技术全梳理；仁会生物技术全梳理；乐普生物技术全梳理；同润生物技术全梳理；宜明昂科技术全梳理；派格生物技术全梳理；迈威生物技术全梳理；Momenta技术全梳理；NGM技术全梳理；普米斯生物技术全梳理；普米斯生物技术全梳理2.0；三叶草生物技术全梳理；贝达药业抗体药全梳理；泽璟制药抗体药全梳理；恒瑞医药抗体药全梳理；齐鲁制药抗体药全梳理；石药集团抗体药全梳理；豪森药业抗体药全梳理；华海药业抗体药全梳理；科伦药业抗体药全梳理；百奥泰技术全梳理；凡恩世技术全梳理。

引进/卖出财报信使RNA抗体药物偶联物临床3期

2024-03-28

·医药笔记

6.5亿美元：吉利德引进Xilio的IL-12前药

▎Armstrong2024年3月28日，吉利德引进Xilio Therapeutics的肿瘤组织特异性活化的IL-12项目XTX-301，吉利德支付3000万美元预付款、1350万美元股权投资，6.04亿美元的转移费、股权投资以及里程碑金额等，以及高个位数至中十位数比例的销售分成。Xilio Therapeutics成立于2016年，3条研发管线处于临床阶段。Xilio Therapeutics建立起肿瘤微环境特异性活化的技术平台，基于TME中异常的MMP来切割释放活性分子。XTX301的设计如下，完整分子没有活性，同时包含长效化domain，在TME中被火化后，长效domain被切掉，效应分子被释放，同时半衰期很短。总结前不久，Janux Therapeutics基于前抗体技术的PSMA/CD3双抗在早期临床中表现出优异的疗效和安全性，再次引起了业界对前抗体技术的关注。细胞因子领域，前抗体技术同样是一条多家biotech广泛采用的技术路径，期待后续临床进展。Armstrong技术全梳理系列GPRC5D靶点全梳理；CD40靶点全梳理；CD47靶点全梳理；补体靶向药物技术全梳理；补体药物：眼科治疗的重要方向；Claudin 6靶点全梳理；Claudin 18.2靶点全梳理；靶点冷暖，行业自知；中国大分子新药研发格局；被炮轰的“me too”；佐剂百年史；胰岛素百年传奇；CUSBEA：风雨四十载；中国新药研发的焦虑；中国生物医药企业的研发竞争；中国双抗竞争格局；中国ADC竞争格局；中国双抗技术全梳理；中国ADC技术全梳理；Ambrx技术全梳理；Vir Biotech技术全梳理；Immune-Onc技术全梳理；亘喜生物技术全梳理；康哲药业技术全梳理；科济药业技术全梳理；恺佧生物技术全梳理；同宜医药技术全梳理；百奥赛图技术全梳理；腾盛博药技术全梳理；创胜集团技术全梳理；永泰生物技术全梳理；中国抗体技术全梳理；德琪医药技术全梳理；德琪医药技术全梳理2.0；和铂医药技术全梳理；荣昌生物技术全梳理；再鼎医药技术全梳理；药明生物技术全梳理；恒瑞医药技术全梳理；豪森药业技术全梳理；正大天晴技术全梳理；吉凯基因技术全梳理；基石药业技术全梳理；百济神州技术全梳理；百济神州技术全梳理第2版；信达生物技术全梳理；信达生物技术全梳理第2版；中山康方技术全梳理；复宏汉霖技术全梳理；先声药业技术全梳理；君实生物技术全梳理；嘉和生物技术全梳理；志道生物技术全梳理；道尔生物技术全梳理；尚健生物技术全梳理；康宁杰瑞技术全梳理；科望医药技术全梳理；科望医药技术全梳理2.0；岸迈生物技术全梳理；礼进生物技术全梳理；康桥资本技术全梳理；余国良的抗体药布局；荃信生物技术全梳理；安源医药技术全梳理；三生国健技术全梳理；仁会生物技术全梳理；乐普生物技术全梳理；同润生物技术全梳理；宜明昂科技术全梳理；派格生物技术全梳理；迈威生物技术全梳理；Momenta技术全梳理；NGM技术全梳理；普米斯生物技术全梳理；普米斯生物技术全梳理2.0；三叶草生物技术全梳理；贝达药业抗体药全梳理；泽璟制药抗体药全梳理；恒瑞医药抗体药全梳理；齐鲁制药抗体药全梳理；石药集团抗体药全梳理；豪森药业抗体药全梳理；华海药业抗体药全梳理；科伦药业抗体药全梳理；百奥泰技术全梳理；凡恩世技术全梳理。

抗体药物偶联物引进/卖出申请上市